Hyloris Pharmaceuticals (HYL) Investor Presentation summary

Company overview

• Focuses on reformulating and repurposing existing drugs to address unmet medical needs, aiming for a global portfolio of 30 cardiovascular and other value-added assets.

• Based in Liège, Belgium, founded in 2012, and listed on Euronext Brussels; co-founders hold 41% of shares.

• Executive team has deep expertise in regulatory affairs, market access, and capital markets, with involvement in over 80 approved drugs and 300+ licensing transactions.

Business model and strategy

• Targets off-patent compounds and generics, focusing on new indications, combinations, and reformulations to lower risk and development costs.

• Repurposing model enables faster innovation, reducing time to market to as little as 7 years compared to 15 years for traditional drug discovery.

• Product selection is based on clear scientific rationale, technical feasibility, and addressable market need, with a cost to market below €7M per asset.

Portfolio highlights

• Cardiovascular pipeline includes Sotalol IV, Aspirin IV, Milrinone ER, Dofetilide IV, and others, with several partnered for commercialization.

• Broader portfolio covers pain management, oncology, infectious diseases, and rare conditions, with products like Maxigesic IV, Podofilox Gel, Alenura, and more.

• Recent pipeline additions target conditions such as Burning Mouth Syndrome (HY-090), Vulvar Lichen Sclerosus (HY-091), and Equine Gastric Ulcer Syndrome (HY-095), all in partnership with AFT Pharmaceuticals.